News >

Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal

Caroline Seymour
Published: Friday, May 17, 2019

Viola W. Zhu, MD, PhD

Viola W. Zhu, MD, PhD

Platinum-doublet chemotherapy is no longer standard of care for patients with advanced squamous non–small cell lung cancer (NSCLC) following the results of the KEYNOTE-407 trial, which demonstrated an improvement in progression-free survival (PFS) and overall survival (OS) irrespective of PD-L1 expression, explained Viola W. Zhu, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication